Enliven Therapeutics, INC Form 4 insider transactions

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, exercised stock options and sold shares on November 27, 2024, under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' CFO, Benjamin Hohl, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Anish Patel, COO of Enliven Therapeutics, reported the sale of 716 shares of common stock at a weighted average price of $30.0035.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc., reported the sale of 847 shares of common stock at a weighted average price of $30.003.

Enliven Therapeutics' CEO, Samuel Kintz, sold 924 shares of common stock at a weighted average price of $30.0029, executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares on October 18, 2024, according to a recent SEC filing.

Director Richard A. Heyman reported the sale of Enliven Therapeutics (ELVN) stock on October 18, 2024, according to a Form 4 filing with the SEC.

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, exercised stock options and sold shares on October 18, 2024, according to a Form 4 filing.

Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics (ELVN) at a weighted average price of $27.6719, according to a Form 4 filing.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on October 8th and 9th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics CEO Samuel Kintz sold shares of common stock on October 8th and 9th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Rahul D. Ballal of Enliven Therapeutics, Inc. executed option exercises and share sales under a pre-arranged Rule 10b5-1 trading plan.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold a portion of his holdings in common stock through transactions on October 4 and October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics CEO Samuel Kintz sold shares of common stock on October 4 and October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Director Richard A. Heyman of Enliven Therapeutics, Inc. reports selling 2,825 shares of common stock at a weighted average price of $27.5057.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 527 shares of common stock at a weighted average price of $27.5372 per share on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics CEO Samuel Kintz sold 526 shares of common stock at an average price of $27.5371 per share on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, executed a transaction involving the exercise of stock options and subsequent sale of common stock on October 1, 2024, according to a Form 4 filing with the SEC.

Director Richard A. Heyman of Enliven Therapeutics, Inc. sold 518 shares of common stock at an average price of $27.5373 per share on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' CFO, Benjamin Hohl, executed option exercises and subsequent stock sales under a pre-arranged Rule 10b5-1 trading plan.

Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics (ELVN) at a weighted average price of $22.408 on September 16, 2024, according to a Form 4 filing.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on August 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics CEO Samuel Kintz sold 12,000 shares of common stock on August 26, 2024, at a weighted average price of $22.8932 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Richard A. Heyman, a director at Enliven Therapeutics, sold shares of the company's common stock on August 15, 2024, according to a Form 4 filing with the SEC.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 3,099 shares of common stock on July 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics CEO Samuel Kintz sold 2,270 shares of common stock at an average price of $27.5573, executed under a pre-arranged 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares on July 31, 2024, according to a Form 4 filing with the SEC.

Richard A. Heyman, a director at Enliven Therapeutics, reported selling shares of common stock on July 31, 2024, under a pre-arranged trading plan.